Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.

P. J. Eppard, S. Hudson, W. J. Cole, R. L. Hintz, G. F. Hartnell, T. W. Hunter, L. E. Metzger, A. R. Torkelson, B. G. Hammond, Robert J Collier

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5% FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.

Original languageEnglish (US)
Pages (from-to)3807-3821
Number of pages15
JournalJournal of Dairy Science
Volume74
Issue number11
StatePublished - Nov 1991
Externally publishedYes

Fingerprint

Lactation
somatotropin
Milk
dairy cows
lactation
Mastitis
dosage
whey
cows
Phosphorus
mastitis
Zinc
zinc
injection
Calcium
calcium
phosphorus
Injections
Milk Proteins
Poisons

ASJC Scopus subject areas

  • Animal Science and Zoology
  • Food Science
  • veterinary(all)

Cite this

Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response. / Eppard, P. J.; Hudson, S.; Cole, W. J.; Hintz, R. L.; Hartnell, G. F.; Hunter, T. W.; Metzger, L. E.; Torkelson, A. R.; Hammond, B. G.; Collier, Robert J.

In: Journal of Dairy Science, Vol. 74, No. 11, 11.1991, p. 3807-3821.

Research output: Contribution to journalArticle

Eppard, PJ, Hudson, S, Cole, WJ, Hintz, RL, Hartnell, GF, Hunter, TW, Metzger, LE, Torkelson, AR, Hammond, BG & Collier, RJ 1991, 'Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.', Journal of Dairy Science, vol. 74, no. 11, pp. 3807-3821.
Eppard, P. J. ; Hudson, S. ; Cole, W. J. ; Hintz, R. L. ; Hartnell, G. F. ; Hunter, T. W. ; Metzger, L. E. ; Torkelson, A. R. ; Hammond, B. G. ; Collier, Robert J. / Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response. In: Journal of Dairy Science. 1991 ; Vol. 74, No. 11. pp. 3807-3821.
@article{b55ea1bca356459db8fb3afe75dffc8f,
title = "Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.",
abstract = "This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5{\%} FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.",
author = "Eppard, {P. J.} and S. Hudson and Cole, {W. J.} and Hintz, {R. L.} and Hartnell, {G. F.} and Hunter, {T. W.} and Metzger, {L. E.} and Torkelson, {A. R.} and Hammond, {B. G.} and Collier, {Robert J}",
year = "1991",
month = "11",
language = "English (US)",
volume = "74",
pages = "3807--3821",
journal = "Journal of Dairy Science",
issn = "0022-0302",
publisher = "Elsevier Limited",
number = "11",

}

TY - JOUR

T1 - Response of dairy cows to high doses of a sustained-release bovine somatotropin administered during two lactations. 1. Production response.

AU - Eppard, P. J.

AU - Hudson, S.

AU - Cole, W. J.

AU - Hintz, R. L.

AU - Hartnell, G. F.

AU - Hunter, T. W.

AU - Metzger, L. E.

AU - Torkelson, A. R.

AU - Hammond, B. G.

AU - Collier, Robert J

PY - 1991/11

Y1 - 1991/11

N2 - This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5% FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.

AB - This study evaluated the effect of sometribove (zinc methionyl bST) in a sustained-release formulation administered to lactating cows at concentrations up to 3.0 g every 14 d over two lactations. Eighty-two lactating Holstein cows in their first, second, or third lactation were assigned to the study. Cows received .6, 1.8, or 3.0 g of bST in one, three, or five intramuscular injections of a unit dose (.6 g) every 2 wk. Controls received five injections of the vehicle (equivalent volume to the 3.0-g treatment) every 2 wk. Injections were administered from 60 +/- 3 d postpartum until dry-off or necropsy. Thirty-eight animals were continued on treatment for a second consecutive lactation. During the 1st yr of treatment, bST increased mean 3.5% FCM by 7.2, 9.4, and 8.4 kg/d over control production (21.1 kg/d). During the 2nd yr, milk response to .6, 1.8, and 3.0 g of bST averaged 10.6, 3.6, and 4.9 kg/d over controls (24.8 kg/d). The incidence of clinical mastitis increased in the 3.0-g group relative to controls during the 2nd yr. Thus, salable FCM averaged 8.1, 9.1, and 6.2 kg/d above controls (yr 1) and 12.1, 4.7, and -2.8 kg/d (yr 2) for the .6-, 1.8-, and 3.0-g groups. Salable FCM was unaffected by mastitis at a proposed commercial dose (.6 g). Milk fat, protein, lactose, calcium, phosphorus, zinc, magnesium, and ash concentrations were unaffected by bST treatment. Calculated energy, calcium, phosphorus, and protein balances also were unaffected except for early decreases of up to 5 Mcal/d, and 40, 20, and 600 g/d, respectively, until feed intake increased. Milk serum bST concentrations greater than the assay limit of sensitivity (1 ng/ml) were routinely measurable only at doses of 1.8 and 3.0 g. Results confirmed that bST concentrations in milk serum are exceedingly small. Overall, supraphysiological doses of sometribove increased milk production with little effect on composition. No toxic effects of bST were observed.

UR - http://www.scopus.com/inward/record.url?scp=0026252265&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026252265&partnerID=8YFLogxK

M3 - Article

C2 - 1757623

AN - SCOPUS:0026252265

VL - 74

SP - 3807

EP - 3821

JO - Journal of Dairy Science

JF - Journal of Dairy Science

SN - 0022-0302

IS - 11

ER -